Core Viewpoint - So-Young International Inc. is postponing the effective date for the planned change in the American depositary shares (ADS) ratio, which was initially set for June 30, 2025 [2][3]. Group 1: ADS Ratio Change - The company intends to change the ADS ratio from thirteen ADSs representing ten Class A ordinary shares to one ADS representing fifteen Class A ordinary shares [2]. - The decision to delay the ADS ratio change is due to the need for additional time to finalize preparations [2]. - An updated timeline for the ADS ratio change will be announced in the future [2]. Group 2: Impact on ADS Holders - The ADS ratio change will function similarly to a proportional reverse ADS split, with no changes to the Class A ordinary shares [3]. - ADS holders will not need to take any action; the exchange of old ADSs for new ADSs will occur automatically [3]. - Fractional new ADSs will not be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [3]. Group 3: Price Expectations - Following the ADS ratio change, the ADS price is expected to increase proportionally, although there is no assurance that the post-change price will match or exceed the proportional price based on the pre-change price [4]. Group 4: Company Overview - So-Young International Inc. is a leading aesthetic treatment platform in China, connecting consumers with online services and offline treatments [5]. - The company offers access to aesthetic treatments through its online platform and branded aesthetic centers, providing curated treatment information and facilitating online reservations [5]. - With strong brand recognition and an efficient supply chain, So-Young is positioned for long-term growth in the medical aesthetic value chain [5].

IRVINE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- SBCMedicalGroupHoldings (Nasdaq:SBC, "the Company") today announces that its Board of Directors has approved the following share repurchase program and will commence repurchasing its own shares as early as May 20, 2025. Share Repurchase Program The Company believes its current share price undervalues its business performance, the growth potential of the aesthetic‑medical market, and its position as an industry leader. Based on this view, it has decided to pur ...

2025 Q1 Earnings May 8, 2025 Forward Looking Statement & Disclosures Except for specific historical information, many of the matters discussed in this presentation may express or imply projections of revenues or expenditures, statements of plans and objectives or future operations or statements of future economic performance. These statements may discuss goals, intentions and expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to ...

Core Viewpoint - Mobile-health Network Solutions (MNDR) intends to acquire Lifepack, a leading pharmacy and telehealth platform in Indonesia, to expand its presence in the high-growth Indonesian healthcare market [1][2][5]. Group 1: Acquisition Details - The acquisition of Lifepack is valued at up to US$7.2 million, contingent upon Lifepack achieving its revenue target for 2025 [5]. - The consideration will be satisfied through the issuance of up to 875,000 new MNDR Class A Ordinary Shares at an issue price of US$8 per share, along with a non-refundable cash payment of US$0.2 million [5][7]. - The US$8 per share issue price represents a substantial premium to MNDR's current share price of approximately US$1.42 as of April 29, 2025, indicating the perceived value of the acquisition [5]. Group 2: Strategic Importance - The acquisition aligns with Indonesia's primary care needs and complements MNDR's telehealth expertise, aiming to serve 280 million people across 17,000 islands [2][3]. - Lifepack's platform is compliant with BPOM regulations and is positioned to lead the Indonesian digital pharmacy market, enhancing healthcare access, especially in remote areas [4][3]. - The partnership aims to create a transformative online-to-offline (O2O) healthcare platform that addresses the unique needs of Indonesia's diverse population [3][4]. Group 3: Lifepack's Operations - Lifepack operates a hybrid model delivering BPOM-licensed prescription drugs, over-the-counter medications, supplements, and medical equipment through both online and offline channels [3][9]. - The platform offers consultations with healthcare professionals via its mobile app, website, and social media, supported by an expanding warehouse network [3][9]. - Lifepack focuses on chronic disease management and preventive care, addressing the growing demand for affordable medical services in Indonesia [3][4].

White Paper Mitigating Risk and Disruption in the MedTech Sector An IQVIA MedTech Canada perspective on navigating the trade uncertainties DHEEMAN VAIDYA, Director, Business Development, IQVIA MedTech ANASTASIA CHERNYATINA, Senior Consultant, IQVIA MedTech Table of contents | Executive summary | 1 | | --- | --- | | Potential impact of new tariffs on MedTech | 1 | | Canada: Impacts on various device categories | 3 | | Canada and the United States: Impact on MedTech manufacturers | 5 | | Canada: Resilience in ...